• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 4, 2013

View Archived Issues

Cytokinetics’ Phase II HF Data: Traders Skeptical, Amgen Not

Cytokinetics Inc. and licensor Amgen Inc. will wait until a Phase II study in chronic heart failure with orally given omecamtiv mecarbil generates data to decide the fate of the compound, which fizzled in a Phase II trial testing the intravenous (I.V.) form of the cardiac myosin activator against acute heart failure (AHF). Read More

BVF Gains Stake in Evotec in $40M Unsolicited Round

LONDON – Evotec AG has received the significant endorsement – and huge financial boost – of an unsolicited €30 million (US$39.5 million) investment from Biotechnology Value Fund LP (BVF). Read More

Acacia’s Series B Adds $24M for PONV Drug; NDA in 2014

LONDON – Acacia Pharma Ltd. raised £15 million (US$23.5 million) in a Series B funding, providing the means to complete Phase III development of its lead product, APD421, for the prevention of postoperative nausea and vomiting (PONV), and to file a new drug application around the middle of 2014. Read More

Syria Crisis to Delay Action on Health Spending

It will be anything but business as usual when Congress reconvenes on Sept. 9, as the debate on military action in Syria is expected to compress the congressional schedule prior to Oct. 1, leading to uncertainty about budget sequestration, funding for health care and research spending. Read More

Baxter, Coherus in Potential $246M Biosimilar Deal

Coherus Biosciences Inc. expanded the horizons for its biosimilar product for Enbrel (etanercept, Amgen Inc.) by inking a potential $246 million deal giving Baxter International Inc. rights to the drug in Europe, Canada, Brazil and other undisclosed markets. Read More

CNS-Focused Company Reverses into Public Domain, Raises $60M

New York-based Intra-Cellular Therapies Inc. (ITI), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, generated gross proceeds of approximately $60 million from a private placement, which included the sale of approximately 18.9 million shares of its common stock to new and existing investors and approximately $15.3 million in bridge notes that converted into common stock at the closing. Read More

In New Place, Platelets Take on a New Role

In work that sheds new light on both immune function and the body’s response to injuries, researchers have shown that platelets play a role in the trafficking of T cells into lymph nodes. Read More

Other News To Note

• Sigma-Aldrich Corp., of St. Louis, said it entered a nonexclusive license agreement with Horizon Discovery Ltd., of Cambridge, UK, for use of Sigma’s Compozr Zinc Finger Nuclease technology. Read More

Stock Movers

Read More

Clinic Roundup

• Esperion Therapeutics Inc., of Plymouth, Mich., reported top-line results from a Phase IIa study of ETC-1002 when added to statin therapy in patients with elevated levels of low-density lipoprotein cholesterol (LDL-C), with data showing that oral, once-daily ETC-1002 achieved incremental LDL-C lowering of 22 percent at eight weeks, compared with 0 percent in the placebo group, when added to 10 mg of atorvastatin (p < 0.0001). Read More

Pharma: Clinic Roundup

• Daiichi Sankyo Co. Ltd., of Tokyo, reported findings from the global Phase III Hokusai-VTE (venous thromboembolism) study of 8,292 patients with acute symptomatic deep vein thrombosis and/or pulmonary embolism. Read More

Pharma: Other News To Note

• Boehringer Ingelheim GmbH, of Ingelheim, Germany, entered a research service agreement with diagnostics firm Diaxonhit, of Paris, for the discovery and characterization of splice variants that have the potential to be therapeutic targets for oncology. With the agreement, Boehringer secures an option to acquire the rights to research, develop and commercialize any targets identified using Diaxonhit’s Splicearray discovery platform. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe